WEBULL
WebtradeDownload

Ligand Pharmaceuticals (LGND) Is Getting Fresh Attention, So What Is Behind It?

Simply Wall St · 1d ago

Ligand Pharmaceuticals (LGND) just closed its largest deal to date, acquiring XOMA Royalty and expanding its portfolio of royalties and late stage programs while also issuing a $700 million zero coupon convertible offering.

The Ligand Pharmaceuticals share price has moved around this year, with a 1 day share price gain of 0.59% and a 30 day share price return of 2.14%. The year to date share price return of 55.17% and 3 year total shareholder return of more than 4x suggest momentum has been strong as investors reassess growth prospects and risk around deals like the XOMA Royalty acquisition and the recent zero coupon convertible raise.

Scan how Ligand Pharmaceuticals compares with other deal driven royalty platforms and late stage pipelines by reviewing the hand picked 20 high quality undiscovered gems that share similar fundamentals.

Ligand Pharmaceuticals now trades at a clear discount to analyst targets and estimated fair value, even after the XOMA Royalty deal and zero coupon raise. Is that simply caution on execution risk, or is the market mispricing the royalty engine that has just been built?

Most Popular Narrative: 14% Undervalued

On the most followed view, Ligand Pharmaceuticals screens as undervalued, with a fair value estimate of $344.25 against a last close of $295. The gap reflects a model built around royalty scale, earnings power and the capital now sitting behind the XOMA Royalty platform.

Expansion of Ligand Pharmaceuticals’ high margin royalty portfolio through the completed XOMA Royalty acquisition, which adds more than 120 assets including additional commercial products and late stage programs, is expected to widen the base of recurring royalty revenue and support higher earnings power as the assets mature.

See why 6 investors see Ligand Pharmaceuticals as 14% undervalued.

Result: Fair Value of $344.25 (UNDERVALUED)

Still, the Ligand Pharmaceuticals story can change quickly if drug pricing pressure affects key royalty streams or if major partnered assets face regulatory setbacks that delay cash flows.

Find out about the key risks to this Ligand Pharmaceuticals narrative.

Another View: What Multiples Say About Ligand Pharmaceuticals

The first take presents Ligand Pharmaceuticals as undervalued, yet its P/E ratio of 29.8x tells a different story. That figure is above both the US pharmaceuticals group at 15.4x and the peer average at 21.3x, and it also exceeds a fair ratio of 22.3x, which may suggest valuation risk if sentiment cools.

For investors weighing that gap between market optimism and earnings reality, See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGM:LGND P/E Ratio as at Oct 2026
NasdaqGM:LGND P/E Ratio as at Oct 2026

Next Steps

Mixed messages in the Ligand Pharmaceuticals story so far. Act while the data is fresh in your mind and stress test both sides of the debate by reviewing the 3 key rewards and 1 important warning sign.

Looking for more Ligand Pharmaceuticals style investment ideas?

If you want to keep sharpening your edge, use the Simply Wall Street Screener to spot other opportunities before they hit everyone’s radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.